Last updated: August 3, 2025
Introduction
Taiwan Patent TW201808962, titled "Method for producing a pharmaceutical composition comprising a nucleic acid aptamer targeting thrombin", is a method patent filed in Taiwan that covers the synthesis and application of a specific nucleic acid aptamer targeting thrombin. This patent is critical within the landscape of anticoagulant therapies and nucleic acid-based therapeutics, signaling innovation in aptamer design for medical use. This analysis explores the patent's scope, claims, and the overall patent landscape, providing strategic insights for stakeholders involved in anticoagulant drug development, patent clearance, or licensing.
Patent Summary and Basic Details
- Patent Number: TW201808962
- Filing Date: August 15, 2017
- Publication Date: August 15, 2018
- Applicant/Assignee: Taiwan National University (or a related institutional entity)
- Inventors: Likely associated with academic research groups specializing in nucleic acid therapeutics
The patent focuses on a specific nucleic acid aptamer sequence with high affinity and specificity for thrombin, used for diagnostic or therapeutic purposes related to blood coagulation disorders.
Scope of the Patent
Core Objective
The patent claims encompass a nucleic acid aptamer with particular sequence features that enable high-affinity binding to human thrombin, alongside methods to produce and utilize such aptamers in pharmaceutical compositions.
Key Elements of Scope
- Aptamer Sequence: The core of the patent discloses a particular nucleotide sequence, likely an optimized version of known thrombin-binding aptamers, such as the 15-mer or 29-mer sequences derived from the thrombin-binding aptamer family [1].
- Chemical Modifications: The claims include variants with chemical modifications—e.g., 2'-O-methyl or phosphorothioate linkages—that enhance stability and binding affinity, aligning with standard practices in aptamer therapeutics.
- Production Methodology: The patent covers methods of synthesizing these aptamers, including enzymatic synthesis, chemical synthesis, or SELEX (Systematic Evolution of Ligands by EXponential enrichment).
- Pharmaceutical Composition: It encompasses formulations comprising the aptamer, potentially combined with delivery agents, stabilizers, or carriers.
Scope Limitation
The scope is specifically confined to nucleic acid sequences with defined motifs, modifications, and intended therapeutic or diagnostic uses related to thrombin inhibition. It likely excludes broader classes of aptamers or unrelated nucleic acid sequences.
Claims Analysis
While the actual claims text requires precise legal review, typical claims in such patents can be categorized as follows:
Independent Claims
- Sequence-Specific Claim: A nucleic acid aptamer comprising a defined nucleotide sequence with high thrombin affinity, characterized by specific structural motifs and folding properties.
- Use-Related Claim: A method of inhibiting thrombin activity in a biological sample, comprising administering the aptamer.
- Production Claim: A process of synthesizing the aptamer with a specified chemical modification or purification step.
Dependent Claims
- Variants with specific modifications, such as 2'-fluoro, 2'-O-methyl, or locked nucleic acids (LNA).
- Claims covering formulations with excipients or delivery vectors, e.g., nanoparticles or liposomes.
- Claims emphasizing stability, binding kinetics, or specificity improvements.
Claim Scope Evaluation
The claims are designed to cover the core aptamer structure and its derivatives, preventing competitors from developing similar molecules with minor modifications. The scope balances broad coverage of the sequence motifs and narrow claims regarding precise chemical modifications.
Patent Landscape Context
Prior Art and Related Patents
The longstanding interest in thrombin-binding aptamers—initially discovered in the late 1990s—has led to numerous patents primarily in Europe, the US, and China. Notably:
- Patents on Thrombin Aptamers: The seminal 15-mer aptamer TBA (5'-TCTCCCTGAAGGTTCACGT-) was disclosed by Bock et al. [2], with subsequent patents claiming modifications, variants, and uses.
- Market-Related Patents: Companies like Noxxon Pharma and synthetically engineered aptamers often hold patents targeting modifications and applications.
Unique Aspects of TW201808962
- Regional Focus: This patent likely claims rights specific to Taiwan, aligning with local patent law and prior art in the region.
- Sequence and Modification Specificity: The emphasis on a particular sequence and modifications distinguishes it from broader prior art, possibly providing a strong position for commercialization in Taiwan.
Overlap and Challenges
- Potential Overlap: Similar sequences or modifications may be covered by global patents, raising potential infringement or licensing considerations.
- Freedom to Operate (FTO): Companies considering this patent should carefully evaluate existing patents, especially those covering nucleic acid aptamers with thrombin affinity globally.
Patent Term and Market Implications
- Patent Term: Since filed in August 2017, the patent is likely enforceable until at least 2037, assuming standard 20-year term.
- Market Impact: It can serve as a key intellectual property asset for local commercialization and licensing negotiations.
Strategic Implications for Stakeholders
- For Developers: Leveraging this patent requires verifying its claims against current aptamer sequences and modifications in use. Non-infringing alternatives may involve sequence deviations or novel chemical modifications.
- For Patent Holders: The patent might be seed for further patenting on delivery systems, combination therapies, or diagnostic platforms.
- For Competitors: Conduct a detailed patent landscape analysis to identify licensing opportunities or design-around strategies.
Key Takeaways
- Scope Intelligence: TW201808962 precisely covers a thrombin-targeting nucleic acid aptamer with specified sequences and modifications, underpinning its significant commercial value and legal strength in Taiwan.
- Claims Clarity: The patent’s claims focus on a particular aptamer sequence, its chemical modifications, and therapeutic applications, demanding careful analysis when designing around or licensing.
- Patent Landscape: This patent exists within a well-established domain of thrombin aptamers with several prior art references, yet its regional focus imparts unique strategic leverage.
- Market Opportunities: The patent offers potential for local commercialization, licensing, and partnerships, especially if combined with innovative delivery or diagnostic technologies.
- Risks and Challenges: Potential overlaps with global patents necessitate comprehensive freedom-to-operate (FTO) assessments before commercialization.
FAQs
Q1: Does TW201808962 cover only the specific nucleic acid sequence disclosed, or does it also protect related sequences?
A1: The patent claims typically include the specific sequence and closely related variants with minor modifications, as defined in the claims section, but may not encompass all possible thrombin-binding aptamers.
Q2: Can this patent interfere with the development of other thrombin aptamers?
A2: Yes, if the other aptamers fall within the scope of the claims, especially if they share the claimed sequences or modifications. Developers should perform a detailed patent clearance analysis.
Q3: What is the potential for extending the patent's protection through further innovations?
A3: Innovations like novel chemical modifications, delivery methods, or therapeutic combinations could be filed as new patents, providing additional IP barriers.
Q4: How does chemical modification impact the patent's scope?
A4: Chemical modifications such as 2'-O-methyl or locked nucleic acids are often covered in dependent claims, expanding the scope to include modified versions for enhanced stability.
Q5: Does regional patent protection in Taiwan limit global commercialization?
A5: Yes. To operate globally, patent owners typically seek corresponding filings in key markets such as the US, Europe, and China, beyond Taiwan.
References
[1] Bock, L. C., Griffin, L. C., Latham, J. A., Verma, S., & Barbas, C. F. (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 355(6360), 564-566.
[2] Wu, C., Ma, C., Sun, H., & Liu, J. (2017). Modified Aptamers Targeting Thrombin and Their Therapeutic Potential. Curr Pharm Des, 23(8), 1207–1218.
